scholarly journals ARB I olmesartan interruption in cardiovascular and cardiorenal continuum: antihypertensive and nephroprotective effects (part 1)

2014 ◽  
Vol 5 (3-4) ◽  
pp. 32-40
Author(s):  
M. G Bubnova
Keyword(s):  
Arterial Hypertension ◽  
Pharmacological Activity ◽  
Safety Profile ◽  
Antihypertensive Drugs ◽  
Angiotensin Receptor Blockers ◽  
Olmesartan Medoxomil ◽  
Angiotensin Receptor ◽  
Protective Properties ◽  
Receptor Blockers ◽  
Adherence Therapy

The article provides an overview of the efficacy and tolerability of one of the representatives of the class angiotensin receptor blockers II - olmesartan medoxomil (Kardosal). Analyzed are the characteristics and pharmacological activity of olmesartan medoxomil antihypertensive monotherapy, in combination with other antihypertensive drugs, in different groups of patients. The article describes the renal protective properties of the drug, its safety profile. It also discusses the reasons for poor adherence therapy in patients with arterial hypertension.

scholarly journals Blood Pressure Control: Stroke and Stroke Prevention

2005 ◽  
Vol 6 (1_suppl) ◽  
pp. S8-S11
Author(s):  
Hans-Christoph Diener
Keyword(s):  
Blood Pressure ◽  
Stroke Prevention ◽  
Antihypertensive Drugs ◽  
Angiotensin Receptor Blockers ◽  
Antihypertensive Agents ◽  
Pressure Control ◽  
Angiotensin Receptor ◽  
Risk Of Death ◽  
Pressure Lowering ◽  
Receptor Blockers

Hypertension is the most important modifiable risk factor for primary and secondary stroke prevention. All antihypertensive drugs are effective in primary prevention: the risk reduction for stroke is 30—42%. However, not all classes of drugs have the same effects: there is some indication that angiotensin receptor blockers may be superior to other classes of antihypertensive drugs in stroke prevention. Seventy-five percent of patients who present to hospital with acute stroke have elevated blood pressure within the first 24—48 hours. Extremes of systolic blood pressure (SBP) increase the risk of death or dependency. The aim of treatment should be to achieve and maintain the SBP in the range 140—160 mmHg. However, fast and drastic blood pressure lowering can have adverse consequences. The PROGRESS trial of secondary prevention with perindopril + indapamide versus placebo + placebo showed a decrease in numbers of stroke recurrences in patients given both active antihypertensive agents, more impressive for cerebral haemorrhage.There were also indications that active treatment might decrease the development of post-stroke dementia.

scholarly journals Azilsartan: Current Evidence and Perspectives in Management of Hypertension

2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
Akshyaya Pradhan ◽  
Ashish Tiwari ◽  
Rishi Sethi
Keyword(s):  
Antihypertensive Drugs ◽  
Angiotensin Receptor Blockers ◽  
Financial Burden ◽  
Daily Practice ◽  
Current Evidence ◽  
Hypertension Management ◽  
Angiotensin Receptor ◽  
Global Pandemic ◽  
Receptor Blockers

Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP). To this end, emergence of more potent antihypertensive drugs is a welcome sign. Angiotensin receptor blockers (ARBs) are cornerstones of hypertension management in daily practice. Among all ARBs, azilsartan is proven to be more potent in most of the head-to-head trials till date. Azilsartan is the latest ARB approved for hypertension with greater potency and minimal side effects. This review highlights the role of azilsartan in management of hypertension in the current era.

scholarly journals Cardiorenal disease development under chronic renin–angiotensin–aldosterone system suppression

2012 ◽  
Vol 13 (1) ◽  
pp. 217-219 ◽  
Author(s):  
Pantelis A Sarafidis ◽  
Luis M Ruilope
Keyword(s):  
Arterial Hypertension ◽  
Enzyme Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
Disease Development ◽  
Converting Enzyme ◽  
Angiotensin Receptor ◽  
Converting Enzyme Inhibitors ◽  
Renin Angiotensin Aldosterone System ◽  
Renin Angiotensin ◽  
Receptor Blockers

Drugs suppressing the renin-angiotensin-aldosterone system (RAAS) are now widely used to treat patients all along the cardiorenal continuum. It supposes that many patients, in particular those with arterial hypertension are treated with converting-enzyme inhibitors and angiotensin receptor blockers for years during which the development and prograssion of cardiorenal disease can be observed. The meaning of this progression in the presence of RAAS suppression requires to be clarified and to be treated in order to diminish the velocity of progression of cardiorenal disease.

Effect of Angiotensin Receptor Blockers on Flow-Mediated Vasodilation: A Meta-Analysis of Randomized Controlled Trials

Cardiology ◽  
2015 ◽  
Vol 131 (2) ◽  
pp. 69-79 ◽  
Author(s):  
Jian-Dong Chen ◽  
Ming Liu ◽  
Xiao-hu Chen ◽  
Zhi-Jian Yang
Keyword(s):  
Endothelial Function ◽  
Antihypertensive Drugs ◽  
Angiotensin Receptor Blockers ◽  
Meta Analysis ◽  
The Other ◽  
Controlled Trials ◽  
Angiotensin Receptor ◽  
Randomized Controlled ◽  
Receptor Blockers ◽  
Flow Mediated Vasodilation

Background: In a meta-analysis, we investigated the effects of angiotensin receptor blockers (ARBs) in comparison to placebo or other classes of antihypertensive drugs on endothelial function, which was measured by brachial flow-mediated vasodilation (FMD). Methods: We searched for randomized controlled trials that compared ARBs with placebo or other classes of antihypertensive drugs in improving FMD. A random-effect model was used to compute pooled estimates. Results: In 13 trials (n = 529), ARBs were more efficacious in improving brachial FMD than placebo [pooled weighted mean change difference (WMD) 1.34%, 95% CI, 0.93-1.75%, p < 0.001]. In 15 trials (n = 918), treatment with ARBs had a significant effect on brachial FMD when compared with other antihypertensive drugs (pooled WMD 0.59%, 95% CI, 0.20-0.98%, p = 0.003 with significant heterogeneity). ARBs were also more efficacious in improving brachial FMD than calcium channel blockers (CCBs; pooled WMD 1.61%, 95% CI, 0.72-2.49%, p < 0.001) but not the other classes of drugs (p ≥ 0.072). Conclusions: This meta-analysis shows that ARBs improve brachial FMD, a marker of endothelial function, and that they are superior to placebo and CCBs. There was no significant difference in the effect on brachial FMD between ARBs and the other antihypertensive drugs.

scholarly journals Management of Hypertension in the Elderly Patient at Abidjan Cardiology Institute (Ivory Coast)

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
K. E. Kramoh ◽  
E. Aké-Traboulsi ◽  
C. Konin ◽  
Y. N'goran ◽  
I. Coulibaly ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Enzyme Inhibitors ◽  
Antihypertensive Drugs ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
The Elderly ◽  
Converting Enzyme ◽  
Angiotensin Receptor ◽  
Converting Enzyme Inhibitors ◽  
Receptor Blockers

Background. Since the treatment of hypertension is beneficial for the elderly, we have undertaken this study that aims to evaluate the management of hypertension in elderly patient in Côte d'Ivoire.Methods. A retrospective study was conducted among 854 hypertensive elderly patients of Abidjan Cardiology Institute who were followed for a minimum of one year, between January 2000 and December 2009.Results. The patients mean age was years, and 59% were women. At the first presentation, it was mostly systolic-diastolic hypertension (51.8%) and isolated systolic hypertension (38.5%). Mean blood pressure was  mmHg for systolic,  mmHg for diastolic, and  mmHg for pulse pressure. Pulse pressure was ≥60 mmHg in 80.4%. According to the European Guidelines stratification of the cardiovascular risk-excess attributable to high blood pressure, 82.1% of the sample had a very high added risk. The pharmacological therapy was prescribed in 93.5%. More than 66% of patients were receiving ≥2 antihypertensive drugs including fixed-dose combination drugs. The most common agents used were diuretics (63.5%) followed by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in 61.3%. The most common agents used for monotherapy were calcium antagonists. When ≥2 drugs were used, diuretics and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers were the most common. Blood pressure control was achieved in 42.6%.Conclusion. The control of elderly hypertension can be effective in Sub-Saharan Africa. He required at least two antihypertensive drugs to meet the recommended blood pressure target.

Sign in / Sign up

Export Citation Format

Share Document